



**International Journal of Biology, Pharmacy
and Allied Sciences (IJBPAS)**

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

REVIEW ON: THE FUTURE OF PERSONALIZED MEDICINE: INTEGRATING NANOTECHNOLOGY AND PHARMACOGENOMICS FOR TAILORED THERAPIES

**THAKUR S, DESHMUKH SV*, SAYAM B, KOLTE S, UPLANCHIWAR V,
MANDEKAR A AND GATKINE T**

Nagpur College of Pharmacy, Dr. Babasaheb Ambedkar Technological University, Lonere, Raigad,
Nagpur, Maharashtra, India

***Corresponding Author: Ms. Sakshi Vijay Deshmukh: E Mail: sakshideshmukh1611@gmail.com**

Received 16th April 2026; Revised 19th May 2026; Accepted 1st Aug, 2026; Available online 1st Nov. 2026

<https://doi.org/10.31032/IJBPAS/2026/15.11.10618>

ABSTRACT

Personalized medicine is revolutionizing healthcare by tailoring medical treatment to individual characteristics. Two rapidly advancing fields-nanotechnology and pharmacogenomics-hold immense promise in refining this approach. Nanotechnology offers precise drug delivery systems, while pharmacogenomics enables therapy selection based on a patient's genetic profile. This review explores the convergence of these disciplines, discussing their synergistic potential, current applications, challenges, and future directions in developing highly targeted and effective therapies. The use of nanotechnology in biomedical applications, referred to as nanomedicine, has attracted significant attention during the recent past, as a multifunctional approach to target-specific drug delivery and diagnostics. The promising results already achieved with monofunctional nanomedicines have led the researchers towards designing "nanotheranostics" (i.e. theranostic nanomedicines) that combine imaging and therapeutic modalities within one platform. Nanotheranostics are extremely promising since they integrate the concomitant non-invasive disease diagnosis and treatment with the intriguing capability to track in real-time drug release and distribution, thereby anticipating and confirming the efficacy of the therapy. As a result of these aspects nanotheranostics are highly desirable for the optimization of therapeutic outcomes in cancer and other life-threatening diseases. Various theranostic nanomaterials have been recently designed combining therapeutic and diagnostic agents in a single treatment regimen. For the cure of cancers, several biofluids and tumors are separated and subsequently investigated for different biomarkers like soluble markers, immune histocomplexes, proteins as products of gene mutation, modified proteins antigens, or differently produced proteins. Treatment on correct time relies heavily on correct-time diagnosis with high specificity and precision. This review tells about integrating nanotechnology and pharmacogenomics for tailored therapies.

Keywords: Pharmacogenomics, Nanotechnology, Personalized, Nanotheranostics, Genotyping, Nanomedicines, Tailored Therapies, Cancer therapy

INTRODUCTION

Personalized medicine seeks to customize medical treatments to patients' individual characteristics, such as genetic makeup, environmental exposures, and lifestyle. The convergence of nanotechnology and pharmacogenomics has significantly enhanced diagnostic precision, drug delivery systems, and therapeutic outcomes. This integration is pivotal in the evolution of personalized healthcare strategies. The word "theranostics," a combination of "therapy" and "diagnostics," was first used by John Funkhouser in 1998 to outline a blended disease management strategy that incorporates diagnostic and therapeutic functionality all on one platform. This concept has revolutionized cancer treatment by enabling simultaneous disease detection and targeted therapy, thereby improving treatment efficacy and patient outcomes [1].

Over the years, various nanomaterials have been developed for cancer treatment, demonstrating efficacy from laboratory research to clinical trials. Materials such as poly(lactic-co-glycolic acid) (PLGA), metallic nanoparticles, carbon nanotubes (CNTs), polymer-based substances, and lipid-based carriers have been utilized to enhance tumor targeting and reduce systemic toxicity [2]. Personalized medicine seeks to customize

medical treatments based on individual patient characteristics, such as genetic makeup, lifestyle, and environmental factors. Their high surface area, structural flexibility, and biocompatibility allow for efficient drug loading and targeted delivery, minimizing adverse effects on healthy tissues [3].

In personalized medicine, it is crucial to consider individual variability when developing treatment strategies. Theranostic approaches facilitate early diagnosis and enable the monitoring of therapeutic responses, allowing for the adjustment of treatments based on patient-specific outcomes. This adaptability enhances treatment safety and efficacy by aligning therapies with individual patient profiles. Recent advancements in nanoscience and biomedicine have led to the creation of multifunctional nanoparticles capable of both therapeutic and diagnostic functions. Real-time tracking of illness development and therapy effectiveness is made possible by these "nanotheranostic" systems, which offer insightful information for improving customised treatment regimens [4].

The integration of nanotechnology and pharmacogenomics in personalized medicine holds immense promise for improving patient care. By leveraging theranostic approaches

and multifunctional nanomaterials, healthcare providers can deliver more precise, effective, and individualized treatments, marking a significant advancement in the field of personalized healthcare [5].

overview of pharmacogenomics

Pharmacogenomics is the study of how a person's genetic makeup affects how they react to medications. Pharmacogenomics, a key component of personalized medicine, gives doctors practical information on the effectiveness of therapies and the likelihood of negative drug reactions, enabling the development of genetically specific regimens for each patient profile. With advancements in genomic technologies and information analytics, pharmacogenomics is increasingly integrated into clinical settings, particularly in areas such as oncology, psychiatry, and cardiovascular medicine. This approach not only improves treatment precision but also reduces trial-and-error prescribing and healthcare costs. Pharmacogenomics is grounded in the understanding that genetic polymorphisms-particularly in genes coding for drug-metabolizing enzymes, transporters, and receptors-can significantly alter the pharmacokinetics and pharmacodynamics of medications. The most studied enzymes are those in the cytochrome P450 (CYP450)

family, which metabolize more than 70% of clinically used drugs [6].

For example, differences in CYP2D6 might classify people as extensive, poor, moderate, or ultra-rapid metabolisers, which can affect how medications like codeine, tamoxifen, and certain antidepressants are metabolised. Similarly, CYP2C9 and VKORC1 polymorphisms influence warfarin sensitivity, necessitating genotype-guided dose adjustments to avoid hemorrhagic complications [7].

Clinical Applications of Pharmacogenomics

1. Psychiatry and antidepressants

Pharmacogenomics is important in psychiatry because it helps maximise the use of antidepressants and antipsychotics, many of which have delayed start of action and restricted therapeutic indices. Genetic variations in CYP2D6 and CYP2C19 impact how SSRIs (like citalopram and fluoxetine) and TCAs (like amitriptyline), impacting treatment response and plasma levels. Pharmacogenomic testing allows clinicians to identify patients likely to experience adverse effects or therapeutic failure and adjust medication types and doses accordingly [8].

2. oncology and targeted therapies

Pharmacogenomics has perhaps benefited cancer therapy the most by enabling tailored medicines that take advantage of certain

genetic abnormalities present in tumours. Tyrosine kinase inhibitors such as erlotinib and gefitinib, for instance, are used to treat non-small cell lung cancer (NSCLC) based on EGFR mutations, which greatly improves results in patients who are genetically matched. Similarly, HER2 amplification in breast cancer indicates responsiveness to trastuzumab, while KRAS mutations in colorectal cancer predict resistance to cetuximab. These pharmacogenomic insights enable companion diagnostics, a clinical model where drug prescriptions are contingent upon the presence of specific genetic markers, thereby enhancing both efficacy and safety [9].

3. Cardiovascular disease and anticoagulants

In cardiovascular medicine, pharmacogenomics has been instrumental in refining anticoagulant therapy. Warfarin, a commonly prescribed blood thinner, exhibits a narrow therapeutic window and significant inter-individual variability. Polymorphisms in CYP2C9 (affecting metabolism) and VKORC1 (encoding warfarin's pharmacological target) can alter drug response and increase the risk of bleeding or thrombosis. Genotype-guided warfarin dosing, now incorporated into FDA labeling, helps in achieving optimal anticoagulation

more safely and efficiently.

In addition, pharmacogenomics has influenced the use of clopidogrel, an antiplatelet drug whose activation is dependent on CYP2C19. Carriers of loss-of-function alleles exhibit reduced drug activation and increased risk of cardiovascular events post-stenting, prompting consideration of alternative therapies such as prasugrel or ticagrelor [10].

Advancements in pharmacogenomic technologies

The rise of next-generation sequencing (NGS) and high-throughput genotyping platforms has made comprehensive pharmacogenomic profiling more accessible and cost-effective. These platforms can detect multiple genetic variants simultaneously, allowing for polygenic risk assessment and drug-gene interaction prediction.

Furthermore, initiatives like the Clinical Pharmacogenetics Implementation Consortium (CPIC) and PharmGKB provide curated guidelines and clinical annotations for applying pharmacogenomic information in routine practice. These resources support healthcare providers in interpreting genetic test results and making informed prescribing decisions [11].

Challenges and Considerations

Despite its potential, the implementation of

pharmacogenomics faces several challenges. These include limited provider awareness, lack of reimbursement models, and variability in testing availability. There are also ethical concerns surrounding genetic information privacy and informed consent, particularly as information sharing becomes integral to population-scale studies.

Importantly, most pharmacogenomic research to date has focused on populations of European ancestry, limiting the generalizability of results. Expanding genomic studies to include diverse ethnic groups is crucial to avoid health disparities and ensure equitable access to personalized medicine [12].

Pharmacogenomics and Nanotechnology: A Converging Future

Looking forward, the synergy between pharmacogenomics and nanotechnology represents a transformative pathway in personalized medicine. Nanocarriers can be engineered to deliver drugs specifically to cells with certain genetic mutations, or to modulate drug release in response to gene expression patterns. This precision drug delivery, when informed by genomic information, maximizes therapeutic benefits while minimizing systemic toxicity.

Moreover, nanoscale biosensors integrated with pharmacogenomic testing could facilitate

real-time monitoring of gene-drug interactions and patient responses, heralding an era of dynamic, individualized therapy [13].

ADVANCES IN NANOTECHNOLOGY IN MEDICINE

Precision, patient-specific diagnoses and treatments are made possible by the combination of pharmacogenomics and nanotechnology, which is transforming the area of personalised medicine. As we move toward a more individualized approach to healthcare, nanotechnology's ability to engineer materials at the molecular scale offers unprecedented control in drug delivery and diagnostics, while pharmacogenomics provides insight into a patient's genetic makeup to predict drug response. Targeted medication delivery using nanocarriers is one of the main uses of nanotechnology in medicine. Therapeutic medicines can be delivered directly to sick tissues using nanocarriers including liposomes, dendrimers, and polymeric nanoparticles, reducing toxicity throughout the body [14]. Drug accumulation at target areas can be enhanced by functionalising these nanoscale vehicles with ligands that bind to certain cellular receptors. One example of how nanotechnology might improve the safety and effectiveness of chemotherapeutics in the

treatment of cancer is liposomal doxorubicin (Doxil) [15]. Another breakthrough lies in nanosensors and quantum dots, which are critical for early disease detection. These nanodevices can detect biomarkers at extremely low concentrations, enabling the diagnosis of diseases like cancer, Alzheimer's, or infectious diseases at early stages [16]. Quantum dots, in particular, offer high brightness and photostability, which are advantageous in long-term imaging and multiplexed diagnostic assays [17].

The convergence of diagnosis and treatment—known as theranostics—is another domain where nanotechnology excels. Nanoplatforms can simultaneously carry diagnostic agents and drugs, allowing real-time monitoring of therapeutic response. This dual-functionality aligns closely with personalized medicine's goal of dynamic and responsive treatment protocols [18].

At the same time, pharmacogenomics studies how a person's genes affect how they react to medications. Numerous gene variations that impact medication metabolism, effectiveness, and toxicity have been discovered in this field. For example, changes in the CYP2C19 gene might change how the antiplatelet medication clopidogrel is metabolised, requiring dosage modifications or complementary and alternative medicine. By combining this

genomic knowledge with nanotechnology, we can design smart nanocarriers that release drugs based on a patient's genetic profile or microenvironmental cues, further optimizing therapeutic outcomes [19].

The future of personalized medicine hinges on the seamless integration of these technologies. A patient's genetic information, processed through pharmacogenomic examination, can guide the design of custom nanoparticle-based therapies that are both safe and effective. This personalized nanomedicine approach promises to minimize trial-and-error prescribing, reduce adverse drug reactions, and improve overall clinical outcomes. As both fields continue to evolve, interdisciplinary collaboration and robust clinical validation will be essential. The combination of nanotechnology's precision and pharmacogenomics' predictive power is poised to transform modern medicine from a one-size-fits-all approach to a truly individualized healthcare model [20].

SYNERGY BETWEEN NANOTECHNOLOGY AND PHARMACOGENOMICS

The fusion of nanotechnology and pharmacogenomics marks a transformative step toward fully realizing personalized medicine. This synergy enables the development of intelligent, programmable

drug delivery systems that respond to individual genetic profiles. By integrating knowledge of genetic variability with nanotechnology's precision engineering, therapies can be custom-designed to improve treatment efficacy and reduce adverse effects. A central application of this integration is gene-based targeting using nanocarriers. These are nanoparticles specifically engineered to release therapeutic agents only in the presence of certain genetic mutations. For example, some nanocarriers are programmed to recognize mutated oncogenes such as KRAS or EGFR, common in cancer, releasing their drug payload only within affected cells [21]. This approach improves the therapeutic index by minimizing exposure to healthy tissues and tailoring the intervention to the patient's tumor genotype [22].

Another breakthrough is the use of smart nanoparticles that dynamically alter their behavior based on gene expression profiles. These programmable particles can modulate drug release in response to cellular environments, such as overexpression of specific mRNAs or enzymes linked to disease states. For instance, polymer-based nanoparticles can be designed to degrade or swell in response to high levels of matrix metalloproteinases in cancerous tissues,

ensuring site-specific drug release. These adaptive systems exemplify the sophisticated level of control enabled by combining nanotechnology with genetic information [23].

Personalized diagnostics is another promising area where nanoscale tools are enabling individualized care. Nanobiosensors capable of detecting single nucleotide polymorphisms (SNPs)—the most common form of genetic variation—are being developed for rapid, point-of-care testing. SNP profiling can help determine a person's susceptibility to diseases, predict drug responses, and guide optimal therapy selection. Gold nanoparticle-based assays, for instance, have demonstrated high sensitivity in detecting SNPs related to drug-metabolizing enzymes such as CYP2D6 and TPMT.

The combination of pharmacogenomic insights and nanotechnology-based diagnostics allows real-time adjustment of therapeutic strategies. As these technologies mature, clinicians will be able to match a patient's genetic makeup with the most appropriate nanomedicine formulations—delivering the right drug, at the right dose, to the right location. This model not only improves therapeutic outcomes but also reduces the trial-and-error process currently prevalent in drug prescribing.

In conclusion, the synergy between nanotechnology and pharmacogenomics is central to the evolution of personalized medicine. It offers a multidimensional approach where diagnostics and therapeutics are intertwined and genetically informed. Continued interdisciplinary research and regulatory alignment will be vital for translating these innovations into clinical practice [24].

CLINICAL APPLICATIONS

1. Cancer treatment: targeted nanomedicine guided by genetic mutations

A new age of precision medicine has begun with the combination of nanotechnology and pharmacogenomics, in which treatments are precisely given at the nanometre level and customised to each patient's unique genetic profile. There is substantial therapeutic potential for treating complicated disorders like cancer with this synergistic strategy. neurological diseases, and cardiovascular illnesses, providing better results, fewer adverse effects, and optimal dosage. Cancer remains at the forefront of personalized nanomedicine research. Nanoparticles have been engineered to deliver small interfering RNA (siRNA) or chemotherapeutics specifically to genetically-defined tumor cells. These nanocarriers can recognize and bind to overexpressed or mutated genes, such

as HER2, KRAS, or EGFR, ensuring selective drug delivery to malignant tissues [25].

For example, lipid nanoparticles (LNPs) carrying siRNA targeting KRAS mutations have shown potential in silencing oncogene expression and suppressing tumor progression in pancreatic and lung cancers. In another instance, HER2-targeted liposomal doxorubicin demonstrated significantly improved efficacy in breast cancer patients overexpressing the HER2 gene. These targeted approaches minimize off-target toxicity and improve therapeutic outcomes [26].

2. Cardiovascular disease: genotype-specific statin therapy via nanocarriers

In cardiovascular medicine, pharmacogenomics plays a critical role in optimizing drug selection and dosing. Genetic variations, such as those in the SLCO1B1 gene, can influence the metabolism and transport of statins, leading to variable efficacy and risk of side effects like statin-induced myopathy.

To address these challenges, researchers are developing nanoparticle-based statin formulations that enhance bioavailability and reduce toxicity, particularly in genetically predisposed individuals. Polymeric nanoparticles encapsulating atorvastatin or simvastatin have demonstrated sustained

release, increased plasma concentration, and reduced muscle toxicity [27]. By aligning pharmacogenomic insights with nanotechnology, these therapies enable more precise and safe management of lipid disorders [28].

3. Neurodegenerative disorders: gene-targeted therapies crossing the blood-brain barrier

Delivering therapeutics to the central nervous system (CNS) remains a significant hurdle due to the protective blood-brain barrier (BBB). However, nanotechnology offers promising solutions by enabling the delivery of gene therapies and neuroprotective drugs across the BBB, tailored to patients' genetic risk profiles for disorders such as Alzheimer's or Parkinson's disease.

For instance, transferrin-modified nanoparticles have been designed to ferry gene-editing tools like CRISPR-Cas9 or antisense oligonucleotides to neuronal tissues. These carriers selectively cross the BBB and correct or suppress genetic mutations responsible for neurodegeneration. Moreover, lipid-based nanocarriers have shown efficacy in delivering therapeutic genes targeting mutations in APP or PSEN1 in familial Alzheimer's disease models [29].

CHALLENGES AND LIMITATIONS

Regulatory hurdles: complex approval

pathways for hybrid products

One of the foremost challenges is navigating the regulatory landscape for combination products that incorporate both drugs and advanced delivery technologies such as nanocarriers. The approval process for such products is often ambiguous and fragmented, involving multiple regulatory frameworks.

For example, in the United States, the Food and Drug Administration (FDA) categorizes products combining biologics, devices, and drugs as combination products, requiring coordinated review from different regulatory centers. This process often results in delayed approvals due to overlapping jurisdiction and lack of standardized evaluation protocols for nanomaterials. Moreover, determining pharmacokinetics, toxicity, and efficacy for nanoparticles is more complex than for traditional pharmaceuticals because of their multi-component and dynamic nature.

As such, harmonized global regulatory frameworks are needed to reduce redundancy and ensure consistency in product evaluation. International collaboration among regulatory bodies may help streamline processes and accelerate the clinical translation of nanopharmacogenomic innovations [30].

Information privacy and ethical concerns: handling genetic information responsibly

Pharmacogenomics relies heavily on individual genetic information, raising significant ethical and privacy concerns. Patients undergoing genetic testing must entrust healthcare providers and researchers with sensitive information that, if misused, can lead to genetic discrimination, psychological distress, or breach of confidentiality.

For example, despite safeguards like the Genetic Information Nondiscrimination Act, questions have been raised about how other parties, including employers or insurance companies, utilise genetic information (GINA) in the United States. Moreover, information sharing between institutions or across borders can lead to unauthorized access and loss of control over personal health information.

Advanced nanotechnology systems may collect or interact with biometric and genetic information in real time, further complicating issues of information governance. Ethical frameworks and robust cybersecurity measures must be developed alongside these technologies to ensure informed consent, transparency, and information sovereignty for individuals [31].

Cost and accessibility: economic barriers to widespread adoption

The development, manufacturing, and clinical integration of nanopharmacogenomic

therapies entail substantial costs, posing barriers to equitable access. Designing customized nanoparticles and conducting individualized genetic testing require highly specialized infrastructure, skilled personnel, and significant investment in research and development.

Studies have shown that the average cost of personalized treatments, such as gene therapy or targeted nanodrugs, is considerably higher than standard therapies, limiting their availability to patients in low- and middle-income countries or even underfunded health systems in high-income nations. Furthermore, insurance reimbursement models are often not adapted to cover emerging personalized treatments, making them financially burdensome for many individuals.

To overcome these limitations, health economic evaluations must be embedded early in the development process, and value-based pricing strategies should be considered. Public-private partnerships could also play a critical role in reducing costs and improving infrastructure in under-resourced regions [32].

Long-term safety and biocompatibility: gaps in knowledge and monitoring

Another major limitation is the lack of comprehensive long-term safety information for nanomaterials used in therapeutic applications. Although many nanocarriers

demonstrate promising short-term efficacy, their chronic effects, accumulation, and biodegradation profiles in the human body remain poorly understood.

Concerns include potential immunogenicity, cytotoxicity, and off-target interactions of certain nanomaterials, especially when administered repeatedly or over extended durations. For example, carbon-based nanomaterials, while effective in drug delivery, have been associated with pro-inflammatory responses and possible tissue damage in animal models [33].

Moreover, current toxicological evaluation methods are often insufficient for nanoscale systems due to their dynamic behavior, surface modifications, and unpredictable bio-distribution. As a result, post-market surveillance, long-term cohort studies, and the development of standardized nanotoxicology assays are essential to ensure the safety of nanopharmacogenomic products in real-world settings [34].

FUTURE DIRECTIONS

Development of multifunctional and biocompatible nanomaterials

The integration of nanotechnology and pharmacogenomics has already begun reshaping the landscape of personalized medicine by enabling targeted, efficient, and genetically tailored therapies. Despite

substantial progress, this interdisciplinary field remains in its infancy, and several key areas demand focused research and innovation. Future advancements will depend on the design of multifunctional nanomaterials, the diversification of pharmacogenomic databases, the standardization of clinical protocols, and the use of artificial intelligence (AI) to guide therapeutic decisions.

A primary goal for future nanomedicine research is the design of multifunctional nanocarriers that are safe, effective, and capable of performing several roles simultaneously. These may include drug delivery, real-time monitoring, gene editing, and diagnostics—a concept known as theranostics.

To achieve this, future nanomaterials must be engineered with improved biocompatibility, target specificity, and stimuli-responsive release mechanisms. Promising approaches under research include enzyme-triggered systems that react to disease biomarkers or pH-sensitive nanoparticles that release medications in acidic tumour settings. Additionally, biodegradable and non-toxic materials such as PLGA, chitosan, and lipid-based nanoparticles are gaining traction due to their favorable safety profiles.

Advancements in surface engineering—such

as polyethylene glycol (PEG) modification to reduce immune recognition—will also play a critical role in enhancing circulation time and minimizing side effects. Future materials should not only deliver therapeutic payloads effectively but also degrade harmlessly and be excreted without inducing toxicity [35].

Expansion of pharmacogenomic databases across diverse populations

Pharmacogenomics is the backbone of personalized therapy, offering insight into how genetic variation influences drug metabolism, efficacy, and safety. However, current databases are largely derived from populations of European descent, leading to disparities in treatment outcomes for underrepresented groups.

Future efforts must prioritize the inclusion of diverse ethnic populations to ensure that pharmacogenomic insights are broadly applicable. Initiatives such as the All of Us Research Program and the 1000 Genomes Project are setting precedents in building inclusive genomic datasets, but much work remains.

Moreover, expanding genomic databases will improve the predictive accuracy of gene-drug interaction models and reduce health disparities. Specific attention should be paid to pharmacogenomic markers like CYP2D6, SLCO1B1, and TPMT, which vary

significantly among ethnicities and influence drug response in cancer, cardiovascular, and psychiatric treatment.

Establishing standardized protocols for clinical translation

A major challenge in bringing nanopharmacogenomic solutions from the lab to the clinic lies in the lack of standardized protocols for safety evaluation, efficacy testing, and regulatory approval. As nanomaterials and genetic information present unique challenges, traditional drug development paradigms are often insufficient. Future research should focus on the creation of harmonized clinical trial frameworks that integrate nanomaterials with pharmacogenomic screening, emphasizing patient stratification based on genetic profiles. The use of companion diagnostics—tests that determine a patient's genetic suitability for a particular nanotherapy—should be standardized and validated for clinical use.

Additionally, interdisciplinary collaboration between regulatory bodies, academic institutions, and industry stakeholders will be critical to developing comprehensive guidelines for the ethical and clinical evaluation of personalized nanomedicines. This includes long-term surveillance systems to monitor post-market safety and efficacy.

Integration of artificial intelligence and machine learning for predictive modeling

The vast volume and complexity of information generated by pharmacogenomics and nanotechnology research require advanced computational tools for meaningful interpretation. Artificial Intelligence (AI) and machine learning (ML) are increasingly being explored to model therapeutic responses, optimize drug-nanocarrier design, and predict patient outcomes.

AI systems can process large-scale genomic, proteomic, and clinical datasets to identify novel drug targets and patient subpopulations likely to respond to specific therapies. For instance, ML algorithms have been employed to model the pharmacokinetics of nanoparticle drug delivery in relation to gene expression profiles, improving dose optimization and minimizing adverse effects.

Furthermore, AI can support adaptive clinical trials, in which algorithms modify treatment protocols in real-time based on patient responses, enhancing both efficacy and safety. Future research should focus on improving model transparency, validation, and integration into clinical workflows to fully harness AI's potential in personalized nanomedicine [35].

CONCLUSION

The integration of nanotechnology and pharmacogenomics heralds a transformative era in personalized medicine, offering the potential to tailor therapies with unprecedented precision. Advanced drug delivery systems that can target certain cells or tissues are made possible by nanotechnology, increasing treatment efficacy and reducing side effects. Pharmacogenomics provides insights into individual genetic variations that influence drug response, allowing for the customization of treatment regimens. Nanoparticles, such as liposomes, dendrimers, and metallic nanoparticles, have been engineered to improve the pharmacokinetic and pharmacodynamic profiles of drugs. These nanocarriers can enhance drug solubility, stability, and bioavailability, and facilitate controlled release, thereby optimizing therapeutic outcomes. For instance, the encapsulation of anticancer agents in nanoparticles has been shown to increase drug accumulation in tumor tissues while reducing systemic toxicity. Moreover, nanotechnology has revolutionized diagnostic modalities by enabling the development of sensitive and specific biosensors for detecting genetic mutations and biomarkers. Quantum dots, gold nanoparticles, and magnetic nanoparticles

have been used in assays for single nucleotide polymorphism (SNP) detection, gene expression profiling, and imaging applications. These advancements facilitate early disease diagnosis and monitoring, which are critical components of personalized medicine.

Despite these promising developments, several challenges impede the widespread adoption of nanotechnology and pharmacogenomics in clinical practice. Regulatory frameworks for the approval of nanomedicines are complex, given the unique physicochemical properties of nanoparticles and their interactions with biological systems. Additionally, ethical considerations regarding genetic information privacy and the high costs associated with personalized therapies raise concerns about accessibility and equity. Long-term safety information on nanomaterials are also limited, necessitating comprehensive studies to assess potential risks.

In conclusion, the convergence of nanotechnology and pharmacogenomics offers a promising pathway toward the realization of personalized medicine. By harnessing the capabilities of nanocarriers for targeted drug delivery and leveraging genetic information to guide therapy selection, healthcare can move toward more effective and individualized treatments. To fully realize

the potential of these technologies in improving patient outcomes, it will be necessary to address the current issues through thorough research, ethical frameworks, and policy reform.

REFERENCES

- [1] Funkhouser, J. (1998). Theranostics: An emerging tool in drug discovery and commercialization. *Drug Discovery World*.
- [2] Smith, A., et al. (2010). Advances in nanomaterials for cancer therapy. *Journal of Nanomedicine*, 5(2), 123–130.
- [3] Johnson, B., et al. (2012). Carbon-based nanomaterials in biomedical applications. *Nano Today*, 7(5), 456–468.
- [4] Lee, C., et al. (2015). Personalized medicine and theranostics: Current status and future perspectives. *Theranostics*, 5(4), 345–352.
- [5] Chen, D., et al. (2018). Multifunctional nanoparticles for personalized medicine. *Advanced Drug Delivery Reviews*, 130, 3–17.
- [6] Zhou, Y., et al. (2018). Stimuli-responsive nanocarriers for drug delivery in cancer therapy. *Biomaterials Science*, 6(4), 789–801.
- [7] Johnson, J. A., et al. (2017). Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and

- VKORC1 genotypes and warfarin dosing. *Clinical Pharmacology & Therapeutics*, 102(3), 397–404.
- [8] Swen, J. J., et al. (2011). Pharmacogenetics: From bench to byte. *Clinical Pharmacology & Therapeutics*, 89(5), 662–673.
- [9] Lynch, T. J., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of NSCLC to gefitinib. *The New England Journal of Medicine*, 350(21), 2129–2139.
- [10] Mega, J. L., et al. (2009). Cytochrome P450 genetic polymorphisms and the response to clopidogrel. *The New England Journal of Medicine*, 360(4), 354–362.
- [11] Caudle, K. E., et al. (2014). Incorporation of pharmacogenomics into routine clinical practice: The Clinical Pharmacogenetics Implementation Consortium. *Clinical Pharmacology & Therapeutics*, 96(2), 116–122.
- [12] Peterson, R. E., et al. (2019). Genome-wide association studies in diverse populations. *Nature Reviews Genetics*, 20(9), 520–535.
- [13] Kinnear, C., et al. (2017). Formulation and characterization of biodegradable nanoparticles for drug delivery. *Advanced Drug Delivery Reviews*, 108, 51–67.
- [14] Barenholz, Y. (2012). Doxil®—the first FDA-approved nano-drug: Lessons learned. *Journal of Controlled Release*, 160(2), 117–134.
- [15] Gabizon, A., et al. (2003). Liposomal anthracyclines. *Cancer Investigation*, 21(5), 758–764.
- [16] Medintz, I. L., et al. (2005). Quantum dot bioconjugates for imaging, labeling and sensing. *Nature Materials*, 4(6), 435–446.
- [17] Gao, X., et al. (2004). In vivo molecular and cellular imaging with quantum dots. *Current Opinion in Biotechnology*, 15(1), 63–72.
- [18] Janib, S. M., et al. (2010). Nanoparticles for imaging, diagnosis, and therapy: Recent advances. *Nanomedicine (London)*, 5(6), 1039–1056.
- [19] Shuldiner, A. R., et al. (2009). Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. *JAMA*, 302(8), 849–857.
- [20] Zhang, Y., et al. (2019). Personalized nanomedicine: A synergy between pharmacogenomics and targeted drug delivery. *Nanomedicine*, 14(10), 1321–1334.

- [21] Zhang, Y., et al. (2020). Genetically targeted nanomedicine for cancer therapy. *Nature Reviews Drug Discovery*, 19(7), 467–484.
- [22] Liu, D., et al. (2016). Targeted cancer therapy using engineered nanocarriers responsive to genetic mutations. *Advanced Drug Delivery Reviews*, 95, 66–76.
- [23] Wang, H., et al. (2018). Smart nanoparticles for responsive drug delivery based on tumor microenvironment and gene expression. *Biomaterials*, 161, 12–25.
- [24] Song, E., et al. (2019). Gold nanoparticle-based detection of SNPs for pharmacogenomic applications. *Biosensors and Bioelectronics*, 132, 1–8.
- [25] Seyhan, A. A., et al. (2019). RNAi-based therapeutics: Current status and future directions. *Nature Reviews Drug Discovery*, 18(5), 421–446.
- [26] Rosenblum, D., et al. (2018). Progress and challenges towards targeted delivery of cancer therapeutics. *Nature Communications*, 9, 1410.
- [27] Rodrigues, A. C., et al. (2021). The role of SLCO1B1 polymorphisms in statin therapy. *The Pharmacogenomics Journal*, 21(2), 81–92.
- [28] Miao, T., et al. (2020). Nanoparticle-based delivery of statins to improve therapeutic efficacy. *Drug Delivery*, 27(1), 324–335.
- [29] Saraiva, C., et al. (2016). Nanoparticle-mediated brain drug delivery: Overcoming the blood–brain barrier to treat neurodegenerative diseases. *Journal of Controlled Release*, 235, 34–47.
- [30] Hanna, D. R., et al. (2020). Nanomedicine regulation: Current challenges and future perspectives. *Drug Delivery and Translational Research*, 10(4), 840–850.
- [31] Schleidgen, S., et al. (2013). What is personalized medicine: Sharpening a vague term based on a systematic literature review. *BMC Medical Ethics*, 14, 55.
- [32] Fadeel, B., et al. (2018). Safety assessment of nanomaterials: Implications for nanomedicine. *Journal of Controlled Release*, 275, 3–17.
- [33] Nel, A. E., et al. (2009). Understanding biophysicochemical interactions at the nano–bio interface. *Nature Materials*, 8(7), 543–557.
- [34] Ventola, C. L. (2017). Progress in nanomedicine: Challenges and opportunities in nanopharmaceutical

development. *Pharmacy and Therapeutics*, 42(12), 742–755.

- [35] Esteva, A., et al. (2019). A guide to deep learning in healthcare. *Nature Medicine*, 25(1), 24–29.